Efficacy and Safety of Aidi Injection as an Adjuvant Therapy on Advanced Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Table 2

Secondary outcomes.

Outcomes	No. of trials	Heterogeneity		Effect size with 95% CI	Z with value
		Chi-squared	I-squared (%)
Immune cells
CD3%	7^12,13,18,21,26−28	514.87 ()	99	3.71 (−3.85∼11.27)	0.96 ()
CD4%	7^12,13,18,21,26−28	1302.78 ()	100	6.67 (−2.71∼16.06)	1.39 ()
CD8%	7^12,13,18,21,26−28	747.57 ()	99	−0.97 (−7.54∼5.6)	0.29 ()
CD4/CD8	7^12,13,18,21,26−28	48.88 ()	88	0.32 (0.07∼0.58)	2.5 (
NK%	4^12,13,18,26	29.39 ()	90	5.54 (4.60∼6.47)	11.64 ()
Tumor markers
CEA	1^13	—	—	−2.39 (−3.99∼−0.79)	2.93 ()
CA153	1^13	—	—	−3.06 (−5.17∼−0.95)	2.85 ()